Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 1
2006 1
2007 4
2008 3
2009 1
2010 3
2011 3
2012 4
2013 5
2014 1
2015 1
2016 1
2017 4
2018 7
2019 7
2020 8
2021 4
2022 10
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
Usuki K, Miyamoto T, Yamauchi T, Ando K, Ogawa Y, Onozawa M, Yamauchi T, Kiyoi H, Yokota A, Ikezoe T, Katsuoka Y, Takada S, Aotsuka N, Morita Y, Ishikawa T, Asada N, Ota S, Dohi A, Morimoto K, Imai S, Kishimoto U, Akashi K, Miyazaki Y; Study Group for NS-87/CPX-351. Usuki K, et al. Among authors: morita y. Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03733-z. Online ahead of print. Int J Hematol. 2024. PMID: 38532078
Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma.
Haeno T, Rai S, Miyake Y, Inoue M, Fujimoto K, Fujii A, Iwata Y, Minamoto S, Taniguchi T, Kakutani H, Inoue H, Kumode T, Serizawa K, Taniguchi Y, Hirase C, Morita Y, Tanaka H, Tatsumi Y, Ashida T, Matsumura I. Haeno T, et al. Among authors: morita y. J Clin Exp Hematop. 2023 Jun 28;63(2):99-107. doi: 10.3960/jslrt.23001. Epub 2023 Apr 28. J Clin Exp Hematop. 2023. PMID: 37121716 Free PMC article.
Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells.
Fujiwara R, Taniguchi Y, Rai S, Iwata Y, Fujii A, Fujimoto K, Kumode T, Serizawa K, Morita Y, Espinoza JL, Tanaka H, Hanamoto H, Matsumura I. Fujiwara R, et al. Among authors: morita y. Biochem Biophys Res Commun. 2022 Oct 20;626:156-166. doi: 10.1016/j.bbrc.2022.08.010. Epub 2022 Aug 10. Biochem Biophys Res Commun. 2022. PMID: 35994825
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.
Morita Y, Nannya Y, Ichikawa M, Hanamoto H, Shibayama H, Maeda Y, Hata T, Miyamoto T, Kawabata H, Takeuchi K, Tanaka H, Kishimoto J, Miyano S, Matsumura I, Ogawa S, Akashi K, Kanakura Y, Mitani K. Morita Y, et al. Int J Hematol. 2022 Nov;116(5):659-668. doi: 10.1007/s12185-022-03414-9. Epub 2022 Jul 12. Int J Hematol. 2022. PMID: 35821550 Free PMC article.
Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.
Ikezoe T, Ando K, Onozawa M, Yamane T, Hosono N, Morita Y, Kiguchi T, Iwasaki H, Miyamoto T, Matsubara K, Sugimoto S, Miyazaki Y, Kizaki M, Akashi K. Ikezoe T, et al. Among authors: morita y. Cancer Sci. 2022 Dec;113(12):4258-4266. doi: 10.1111/cas.15458. Epub 2022 Oct 10. Cancer Sci. 2022. PMID: 35689544 Free PMC article. Clinical Trial.
Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells.
Taniguchi T, Nakayama S, Tanaka H, Rai S, Hirase C, Morita Y, Tatsumi Y, Ashida T, Matsuda M, Hashimoto S, Matsumura I. Taniguchi T, et al. Among authors: morita y. Br J Haematol. 2022 Jul;198(2):360-372. doi: 10.1111/bjh.18208. Epub 2022 Apr 22. Br J Haematol. 2022. PMID: 35451502
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
Yoshida C, Kondo T, Ito T, Kizaki M, Yamamoto K, Miyamoto T, Morita Y, Eto T, Katsuoka Y, Takezako N, Uoshima N, Imada K, Ando J, Komeno T, Mori A, Ishikawa Y, Satake A, Watanabe J, Kawakami Y, Morita T, Taneike I, Nakayama M, Duan Y, Garbayo Guijarro B, Delgado A, Llamas C, Kiyoi H. Yoshida C, et al. Among authors: morita y. Int J Hematol. 2022 Jul;116(1):89-101. doi: 10.1007/s12185-022-03334-8. Epub 2022 Apr 8. Int J Hematol. 2022. PMID: 35394258
A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia.
Iida H, Imada K, Ueda Y, Kubo K, Yokota A, Ito Y, Kiguchi T, Hata T, Nawa Y, Ikezoe T, Uchida T, Morita Y, Kawashima I, Chiba M, Morimoto K, Hirooka S, Miyazaki Y, Ohno R, Naoe T; Study Group. Iida H, et al. Among authors: morita y. Int J Hematol. 2022 May;115(5):694-703. doi: 10.1007/s12185-022-03307-x. Epub 2022 Feb 24. Int J Hematol. 2022. PMID: 35211840 Clinical Trial.
62 results